US20200318044A1 - Method for aggregating cell mass and device for aggregating cell mass - Google Patents

Method for aggregating cell mass and device for aggregating cell mass Download PDF

Info

Publication number
US20200318044A1
US20200318044A1 US16/765,495 US201816765495A US2020318044A1 US 20200318044 A1 US20200318044 A1 US 20200318044A1 US 201816765495 A US201816765495 A US 201816765495A US 2020318044 A1 US2020318044 A1 US 2020318044A1
Authority
US
United States
Prior art keywords
specific gravity
aggregating
cell masses
rotating body
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/765,495
Other languages
English (en)
Inventor
Hideki Taniguchi
Tomomi Tadokoro
Tetsuya Sakashita
Satoshi Matsumoto
Satoshi Adachi
Akira HIGASHIBATA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Aerospace Exploration Agency JAXA
Yokohama City University
Original Assignee
Japan Aerospace Exploration Agency JAXA
Yokohama City University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Aerospace Exploration Agency JAXA, Yokohama City University filed Critical Japan Aerospace Exploration Agency JAXA
Assigned to PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, JAPAN AEROSPACE EXPLORATION AGENCY reassignment PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ADACHI, SATOSHI, HIGASHIBATA, AKIRA, MATSUMOTO, SATOSHI, SAKASHITA, TETSUYA, TADOKORO, Tomomi, TANIGUCHI, HIDEKI
Publication of US20200318044A1 publication Critical patent/US20200318044A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00—Bioreactors or fermenters specially adapted for specific uses
    • C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
    • C12M27/10—Rotating vessel
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M37/00—Means for sterilizing, maintaining sterile conditions or avoiding chemical or biological contamination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/40—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/48—Automatic or computerized control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2535/00—Supports or coatings for cell culture characterised by topography
    • C12N2535/10—Patterned coating

Definitions

  • the present invention relates to a method for aggregating cell masses and a device for aggregating cell masses.
  • the device for culturing cells described in Patent Document 1 is a single-shaft rotary bioreactor having a gas exchange function.
  • a liquid culture medium is filled in a horizontal cylindrical bioreactor.
  • culturing is performed while rotating the bioreactor along the horizontal axis of the bioreactor. Due to the rotation of the bioreactor, the direction of gravity applied to the cells (mass) in the bioreactor periodically changes, so that the cells are held in a relatively minute range with respect to the bioreactor. That is, sedimentation of the cells is suppressed.
  • the cells are uniformly suspended in a liquid culture medium, cultured and grown for a required time, and fused to form a tissue mass.
  • the culturing device described in Patent Document 2 uses a clinostat equipped with a liquid culture medium circulation system.
  • the clinostat includes support columns installed on the main body, an outer frame, and an inner frame.
  • the outer frame is rotatably supported with respect to the support columns.
  • the inner frame is rotatably supported with respect to the outer frame.
  • the culturing vessel rotates in the same manner as the inner frame.
  • a liquid culture medium and cell masses to be cultured are sealed inside the culturing vessel.
  • Patent Document 1 PCT International Publication No. WO 2005/056072
  • Patent Document 2 Japanese Unexamined Patent Application, First Publication No. 2006-304791
  • Patent Document 1 and Patent Document 2 each realize a microgravity environment in a culturing vessel and culture cell masses in the environment.
  • Patent Document 2 there is a problem that the cell masses dispersed in the specific gravity adjustment solution cannot be aggregated at a predetermined position.
  • the present invention has been made in view of such a problem, and an object thereof is to provide a method for aggregating cell masses capable of aggregating cell masses at a predetermined position in a specific gravity adjustment solution, and a device therefor.
  • the present invention proposes the following means.
  • a method for aggregating cell masses of the present invention includes: performing a cell mass aggregating step of rotating a rotating body containing a specific gravity adjustment solution and cell masses to aggregate the cell masses, the specific gravity adjustment solution having biocompatibility, the cell masses having a lower specific gravity than the specific gravity adjustment solution.
  • a device for aggregating cell masses includes: a rotating body configured to contain a specific gravity adjustment solution having biocompatibility and cell masses having a lower specific gravity than the specific gravity adjustment solution.
  • the cell masses when the rotating body is rotated, the cell masses move to a predetermined position in the specific gravity adjustment liquid with respect to the specific gravity adjustment liquid due to the centripetal force that arises from the difference between the specific gravity of the specific gravity adjustment liquid and the specific gravity of the cell masses. Since the specific gravity adjustment solution has biocompatibility, the cell masses collected at the predetermined position continue to survive in the specific gravity adjustment solution. Therefore, the cell masses can be aggregated at the predetermined position in the specific gravity adjustment solution.
  • the rotating body in the cell mass aggregating step, may be rotated about a central axis of the rotating body to aggregate the cell masses around the central axis.
  • the cell masses can be aggregated around the central axis.
  • the cell mass aggregating step may be performed in a state of a base material arranged on the central axis of the rotating body.
  • the above-described device for aggregating cell masses may include a mounting portion for mounting a base material on a central axis of the rotating body.
  • cell masses can be aggregated around the base material.
  • the cell mass aggregating step may be performed while supplying a liquid culture medium into the base material.
  • the above-described device for aggregating cell masses may include a supply portion for supplying a liquid culture medium into the base material.
  • nutrients, oxygen, and the like in the liquid culture medium can be supplied through the base material, and so necrosis of the cell mass can be suppressed.
  • the above-described method for aggregating cell masses may include performing a deaeration step of rotating the rotating body to collect air in the rotating body on the base material and remove the air from the rotating body through the base material.
  • the present invention even if air is contained in the rotating body, it is possible to inhibit disturbances in the flow within the specific gravity adjustment liquid due to the air and it is possible to reliably aggregate cells.
  • the deaeration step may be performed before the cell mass aggregating step.
  • the cell masses can be more reliably aggregated from a state where there is no air in the rotating body.
  • the base material may be an artificial blood vessel or a regeneration blood vessel.
  • the method for aggregating cell masses and the device for aggregating cell masses of the present invention it is possible to aggregate cell masses at a predetermined position in a specific gravity adjustment solution.
  • FIG. 1 is a partial cutaway perspective view of a device for aggregating cell masses according to an embodiment of the present invention.
  • FIG. 2 is a perspective view for describing a step of generating cell masses by mixing cells derived from induced pluripotent stem cells, vascular endothelial cells, and mesenchymal cells.
  • FIG. 3 is a flowchart showing a method for aggregating cell masses according to an embodiment of the present invention.
  • FIG. 4 is a perspective view for describing a state in which a plurality of cell masses are aggregated on an artificial blood vessel by cell masses aggregating step in the method for aggregating cell masses.
  • FIG. 5 is a perspective view showing a simulation result of the method for aggregating cell masses, showing a state before the rotating body rotates.
  • FIG. 6 is a perspective view showing a simulation result of the method for aggregating cell masses, showing a state four minutes after rotation of the rotating body.
  • FIG. 7 is a perspective view showing a simulation result of the method for aggregating cell masses, showing a state eight minutes after rotation of the rotating body.
  • FIG. 8 is a perspective view showing a simulation result of the method for aggregating cell masses, showing a state 12 minutes after rotation of the rotating body.
  • FIG. 9 is a photograph showing a perspective view of a state in which the rotating body having been rotated in the state of the rotating body filled with a specific gravity adjustment liquid and a plurality of cell masses injected therein.
  • FIG. 10 is a photograph showing a perspective view of a state in which cell masses are aggregated on the artificial blood vessel.
  • FIG. 11 is a photograph showing a state, viewed from the front, in which cell masses are aggregated on the artificial blood vessel.
  • FIG. 12 is a photograph showing a state, viewed from the side, in which cell masses retain fluorescence expression.
  • the aggregating device 1 of the present embodiment includes a rotating body 11 , a pair of mounting portions 21 and 22 , and a supply portion 26 .
  • the shape of the rotating body 11 is not particularly limited as long as a housing space for housing a specific gravity adjustment solution and cells (cell masses) described later is formed.
  • the rotating body 11 includes a first side portion 12 , a second side portion 13 , and an outer peripheral plate 14 .
  • the side portions 12 and 13 are formed in a circular shape and are arranged so as to face each other.
  • the outer peripheral plate 14 is formed in a cylindrical shape. Each end of the outer peripheral plate 14 in the axial direction is connected to the outer peripheral edge of the first side portion 12 and the outer peripheral edge of the second side portion 13 , respectively.
  • the rotating body 11 is formed in a hollow cylindrical shape by resin or the like.
  • an injection port 15 is formed in the outer peripheral plate 14 with rubber or the like.
  • the injection port 15 penetrates the outer peripheral plate 14 and reaches the internal space of the rotating body 11 .
  • the rotating body 11 be provided with a lid that can be opened and closed. When the lid is closed, the lid is liquid-tightly connected to portions of the rotating body 11 other than the lid.
  • the material forming the side portions 12 and 13 and the outer peripheral plate 14 of the rotating body 11 is not particularly limited, and may be metal, acrylic resin, or the like. However, from the viewpoint of biocompatibility and internal visibility, it is preferable that the rotating body 11 be formed of resin by injection molding.
  • Cells referred to in the present specification are not particularly limited provided the cells can form spheroids, and for example include animal-derived cells, including mammals such as humans, monkeys, cows, horses, pigs, sheep, dogs, cats, rabbits, rats, mice, and hamsters.
  • the cells may be established as cultured cells or primary cells obtained from biological tissues.
  • neural stem cells or the like as embryonic stem cells (ES cells), induced pluripotent stem cells (hereinafter referred to as iPS cells), and mesenchymal stem cells, and it is possible to use hepatocytes, pancreatic islet cells, kidney cells, nerve cells, corneal endothelial cells, chondrocytes, cardiomyocytes, and the like, as differentiated cells.
  • ES cells embryonic stem cells
  • iPS cells induced pluripotent stem cells
  • mesenchymal stem cells hepatocytes, pancreatic islet cells, kidney cells, nerve cells, corneal endothelial cells, chondrocytes, cardiomyocytes, and the like, as differentiated cells.
  • hepatocytes pancreatic islet cells
  • kidney cells nerve cells
  • corneal endothelial cells chondrocytes
  • cardiomyocytes cardiomyocytes
  • cells that are induced to differentiate from cord blood, bone marrow, fat, and blood-derived tissue stem cells can
  • the rotating body 11 is rotatably supported about a central axis C by a support table (not shown).
  • the rotating body 11 is rotated about the central axis C by a driving unit such as a motor.
  • the driving unit transmits driving force by contacting the outer surface of the outer peripheral plate 14 of the rotating body 11 to rotate the outer surface thereof or by rotating a belt wound around a pulley fixed coaxially with the rotating body 11 .
  • the mounting portions 21 and 22 are formed in a cylindrical shape, and are respectively arranged on the central axis C of the rotating body 11 .
  • the first mounting portion 21 is fixed to a surface of the first side portion 12 facing the second side portion 13 .
  • the second mounting portion 22 is fixed to a surface of the second side portion 13 facing the first side portion 12 .
  • a gap is formed between the first mounting portion 21 and the second mounting portion 22 .
  • the mounting portions 21 and 22 are formed of the same material as the rotating body 11 .
  • An artificial blood vessel (base material) D is attached to the mounting portions 21 and 22 .
  • artificial blood vessel as used herein means a blood vessel formed from synthetic fibers, biomaterials, or the like.
  • the artificial blood vessel D is formed in a tubular shape from a material having gas permeability.
  • the artificial blood vessel D is attached to the mounting portions 21 and 22 such as by fitting each end of the artificial blood vessel D to the mounting portions 21 and 22 from the outer side in the radial direction.
  • the base material is the artificial blood vessel D
  • the base material is not limited thereto, and may be a regenerated blood vessel or the like.
  • the regeneration blood vessel mentioned here means a blood vessel formed by regenerative medicine.
  • a stock solution W is accommodated in the rotating body 11 .
  • the stock solution W includes a specific gravity adjustment solution W 1 and cell masses W 2 .
  • the cell mass W 2 is obtained by aggregating and co-culturing in a well or a like a mixture W 2 a , which is obtained by mixing iPS cell-derived cells W 4 , vascular endothelial cells (HUVEC) W 5 , and mesenchymal cells (MSC) W 6 at a predetermined ratio.
  • W 2 a which is obtained by mixing iPS cell-derived cells W 4 , vascular endothelial cells (HUVEC) W 5 , and mesenchymal cells (MSC) W 6 at a predetermined ratio.
  • vascular endothelial cell means a cell constituting the vascular endothelium or a cell capable of differentiating into such a cell.
  • mesenchymal cell as used herein means a connective tissue cell that mainly exists in the connective tissue derived from the mesoderm and forms a support structure for cells that function in a tissue, and is a concept that includes cells whose differentiation fate into mesenchymal cells has been determined but have not yet differentiated into mesenchymal cells.
  • the specific gravity of the cell mass W 2 is smaller than the specific gravity of the specific gravity adjustment solution W 1 .
  • the specific gravity of the cell mass W 2 is 1.05.
  • the specific gravity adjustment liquid W 1 includes a first liquid culture medium and a biocompatible specific gravity adjustment agent.
  • the specific gravity adjustment liquid W 1 may include a pH adjustment agent, a suspending agent, and the like in addition to the first liquid culture medium and the specific gravity adjustment agent.
  • the specific gravity adjustment agent W 1 may be Iodixanol, Ficoll, or the like.
  • the first liquid culture medium mentioned here and a second liquid culture medium described below are not particularly limited, and can be appropriately selected according to the cell (mass) to be cultured.
  • Examples of publicly known culture media include MEM, ⁇ -MEM, DMEM, RPM1, cRDF, ERDF, F12, MCDB131, F12/DMEM, and WE.
  • mTeSR1 manufactured by Stem Cell Tech.
  • Essential 8 registered trademark, manufactured by Life Technologies
  • Repro FF/FF2/XF manufactured by Reprocell
  • StemSure registered trademark, manufactured by Wako Pure Chemical Industries, Ltd.
  • CELRENA manufactured by Cell Science & Technology Institute
  • S-Medium manufactured by DS Pharma
  • StemFit manufactured by Ajinomoto
  • biocompatibility means not imparting a strong adverse effect or strong stimulus to a living body, and therefore means the attribute of being capable of coexisting with at least one of a biological component, a biological tissue such as a cell (lump), and a substance derived from an organism.
  • the first liquid culture medium one that differentiates the cell mass W 2 into a liver cell is used.
  • the specific gravity of the first liquid culture medium is about 1.0.
  • the specific gravity adjustment agent is preferably a density gradient medium for cell separation.
  • OptiPrep registered trademark, manufactured by Cosmo Bio Inc.
  • the specific gravity of the specific gravity adjustment liquid W 1 is 1.06 or more and 1.08 or less.
  • the specific gravity of the cell mass W 2 is smaller than the specific gravity of the specific gravity adjustment solution W 1 , the specific gravity of the specific gravity adjustment solution W 1 can be, for example, 1.03 or more and 1.15 or less, or 1.01 or more and 1.20 or less.
  • the concentration of the specific gravity adjustment agent in the specific gravity adjustment solution W 1 is preferably such that the specific gravity adjustment solution W 1 does not harm the cell mass W 2 .
  • the supply portion 26 includes a main body 27 , a supply pipe 28 , and a discharge pipe 29 .
  • the supply pipe 28 and the first mounting portion 21 communicate with each other.
  • the discharge pipe 29 and the second mounting portion 22 communicate with each other.
  • the main body 27 includes a supply tank, a pump, and a waste tank.
  • a second liquid culture medium (liquid culture medium) is contained in the supply tank.
  • the second liquid culture medium is not particularly limited, but may be the same as the first liquid culture medium.
  • the pump supplies the second liquid culture medium in the supply tank to the supply pipe 28 at a constant flow rate.
  • the supply portion 26 supplies the second liquid culture medium into the rotating body 11 .
  • the used second liquid culture medium returned to the main body 27 through the discharge pipe 29 is stored in the waste tank.
  • the supply unit 26 may supply blood, artificial blood, or the like instead of the second liquid culture medium.
  • FIG. 3 is a flowchart showing the aggregating method S according to the embodiment of the present invention.
  • Step S 1 the lid of the rotating body 11 is opened, and each end of the artificial blood vessel D is fitted onto the mounting portions 21 and 22 .
  • the artificial blood vessel D is arranged on the central axis C of the rotating body 11 .
  • the space between each end of the artificial blood vessel D and the attachment portions 21 and 22 is sealed in a liquid-tight manner.
  • the lid of the rotating body 11 is closed.
  • the rotating body 11 is filled with the specific gravity adjustment liquid W 1 through the injection port 15 using a syringe or the like. At this time, it is preferable to fill the specific gravity adjustment liquid W 1 so that no air bubbles remain in the rotating body 11 .
  • the rotating body 11 containing the specific gravity adjustment liquid W 1 is rotated about the central axis C by the driving unit. Since the specific gravity of the air is smaller than the specific gravity of the specific gravity adjustment liquid W 1 , the air moves from the outer side in the radial direction of the central axis C toward the central axis C with respect to the specific gravity adjustment liquid W 1 due to the centripetal force acting on the air.
  • the air in the rotating body 11 is collected on the artificial blood vessel D. Since the artificial blood vessel D has gas permeability, air is removed from the inside of the rotating body 11 through the blood vessel wall of the artificial blood vessel D into the artificial blood vessel D.
  • This deaeration step S 5 is performed before a cell mass aggregating step S 9 described below.
  • Step S 7 a plurality of the cell masses W 2 are injected into the rotating body 11 through the injection port 15 using a syringe or the like. Since the specific gravity adjustment liquid W 1 in the rotating body 11 has biocompatibility, the plurality of cell masses W 2 can continue to survive in the specific gravity adjustment liquid W 1 .
  • the rotating body 11 containing the specific gravity adjustment liquid W 1 and the plurality of cell masses W 2 is rotated about the central axis C by the driving portion. Since the specific gravity of the cell mass W 2 is smaller than the specific gravity of the specific gravity adjustment solution W 1 , the plurality of the cell masses W 2 move toward the central axis C with respect to the specific gravity adjustment solution W 1 due to the centripetal force acting on the cell masses W 2 . As shown in FIG. 4 , the plurality of cell masses W 2 aggregate on the outer peripheral surface of the artificial blood vessel D, which is arranged on the central axis C.
  • the cell mass aggregating step S 9 may be performed while the supply portion 26 supplies the second liquid culture medium into the artificial blood vessel D. By doing so, nutrients, oxygen, and the like in the second liquid culture medium are supplied to the cell masses W 2 .
  • the aggregating method S of the present embodiment is performed in a place where gravity does not act, such as in outer space, or a place where only gravity smaller than the gravity of the earth acts, even if the rotating body 11 does not rotate about the central axis C, the cell masses W 2 hardly settle in the specific gravity adjustment solution W 1 . By rotating the rotating body 11 about the central axis C, the cell masses W 2 can be aggregated in a stable manner.
  • the diameter of the rotating body 11 was set to 20 mm and the thickness was set to 10 mm, while the thicknesses of the side portions 12 and 13 and the outer peripheral plate 14 were ignored. It was assumed that the rotating body 11 was arranged such that the central axis C was along the horizontal plane.
  • the diameter of the cell mass W 2 was set to 100 ⁇ m (micrometers) and the specific gravity was set to 1.05.
  • the number of cell clusters W 2 supplied into the rotating body 11 was set to 600.
  • the specific gravity of the specific gravity adjustment liquid W 1 was set to 1.08.
  • the diameter of the artificial blood vessel D was set to 1 mm. It was assumed that gravity acted at 1 G (9.8 m/s 2 ) toward the lower part A shown in FIG. 5 .
  • the rotation speed of the rotating body 11 about the central axis C was set to 150 rpm (rotations/minute).
  • FIGS. 6, 7, and 8 show the state where the rotating body 11 has rotated about the central axis C for 4, 8, and 12 minutes, respectively. As the time of the rotating body 11 rotating about the central axis C increases, the plurality of cell masses W 2 move so as to approach the artificial blood vessel D. It was found that, in the state shown in FIG. 8 rotated for 12 minutes, the cell masses W 2 aggregated around the artificial blood vessel D.
  • the plurality of cell masses W 2 move toward the central axis C from the outer side in the radial direction of the central axis C with respect to the specific gravity adjustment liquid W 1 due to the centripetal force that arises from a difference between the specific gravity of the specific gravity adjustment solution W 1 and the specific gravity of the cell mass W 2 . Since the specific gravity adjustment solution W 1 has biocompatibility, a plurality of the cell masses W 2 can be aggregated on the central axis C while still living.
  • the cell mass aggregating step S 9 is performed in a state in which the artificial blood vessel D is arranged on the central axis C of the rotating body 11 by the mounting portions 21 and 22 . Thereby, a plurality of cell masses W 2 can be aggregated on the artificial blood vessel D.
  • the cell mass aggregating step S 9 is performed while supplying the second liquid culture medium into the artificial blood vessel D by the supply portion 26 . Therefore, nutrients, oxygen, and the like in the second liquid culture medium can be supplied to the plurality of cell masses W 2 through the artificial blood vessel D.
  • the deaeration step S 5 is performed in the aggregating method S. Accordingly, even if air is contained in the rotating body 11 , by inhibiting disturbances in the flow within the specific gravity adjustment liquid W 1 due to the air, the cell masses W 2 can be reliably aggregated.
  • the deaeration step S 5 is performed before the cell mass aggregating step S 9 . Accordingly, the cell masses W 2 can be more reliably aggregated in the cell mass aggregating step S 9 from the state where there is no air in the rotating body 11 .
  • the aggregating device 1 may not include the mounting portions 21 and 22 .
  • the mounting step S 1 is not performed in the aggregating method S.
  • the aggregating device 1 may not include the supply portion 26 .
  • the deaeration step S 5 may be performed simultaneously with the cell mass aggregating step S 9 , and the deaeration step S 5 may not be performed.
  • the specific gravity adjustment liquid may include the first liquid culture medium without including the specific gravity adjustment agent.
  • An artificial blood vessel was placed on the central axis of the rotating body.
  • Hepatic progenitor cells derived from iPS cells, vascular endothelial cells and mesenchymal cells were mixed at a predetermined ratio to prepare the cell masses.
  • the rotating body was filled with the specific gravity adjustment liquid, and the rotating body was rotated in a state in which a plurality of cell masses were injected. The rotating body was rotated at a rotation speed of 150 rpm for 12 minutes.
  • the criteria for determining a specific gravity adjustment agent (specific gravity adjustment liquid) as being acceptable are that the specific gravity adjustment agent has biocompatibility, has a higher specific gravity than the cell mass, and that a plurality of cell masses survive in the specific gravity adjustment agent.
  • Lymphocyte Separation Solution manufactured by Nacalai Tesque Inc.
  • the first liquid culture medium 70% (% by weight)
  • 30% of the specific gravity adjustment liquid is the first liquid culture medium.
  • the specific gravity of the specific gravity adjustment solution was 1.06, and the pH was 7.8.
  • OptiPrep registered trademark, manufactured by Cosmo Bio Company, Limited
  • the specific gravity of the specific gravity adjustment solution was 1.06 to 1.07, and the pH was 7.8.
  • cell masses including vascular endothelial cells expressing Kusabira-Orange, mesenchymal cells, and hepatic progenitor cells derived from TkDA 3-4 cells (iPS cells) that expressed EGFP aggregated on the artificial blood vessel, as shown in FIGS. 10 and 11 .
  • FIGS. 10 and 11 hepatic progenitor cells derived from TkDA 3-4 cells
  • OptiPrep of Sample No. 3 was mixed with the first liquid culture medium at 15% to prepare a specific gravity adjustment liquid.
  • the specific gravity of the specific gravity adjustment solution was 1.07 to 1.08, and the pH was 7.8.
  • vascular endothelial cells, mesenchymal cells, and TkDA 3-4 cells expressing EGFP were found to slightly differ from the normal form, but a plurality of the cell masses survived, and so a passing evaluation was given.
  • the specific gravity adjustment agent Percoll (registered trademark, manufactured by GE Healthcare Co., Ltd.) of Sample No. 4 was mixed with the first liquid culture medium at 70% to prepare a specific gravity adjustment liquid.
  • the specific gravity of the specific gravity adjustment solution was 1.07 to 1.08, and the pH was 8.1.
  • the vascular endothelial cells and mesenchymal cells were found to slightly differ from the normal form, but a plurality of cell masses survived, and so a passing evaluation was given.
  • sodium polytungstate of Sample No. 5 was mixed with the first liquid culture medium at 6% to 8% to prepare a specific gravity adjustment liquid.
  • the specific gravity of the specific gravity adjustment solution was 1.06, and the pH was 6.6.
  • methyl cellulose of Sample No. 6 was mixed with the first liquid culture medium at 0.10% to prepare a specific gravity adjustment liquid.
  • the specific gravity of the specific gravity adjustment liquid was 0.98. Since cell masses having a specific gravity lower than that of the specific gravity adjustment solution were not anticipated, a failing evaluation was given.
  • the method for aggregating cell masses and the device for aggregating cell masses according to the present embodiment can be suitably used for aggregating cell masses.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Sustainable Development (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Computer Hardware Design (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US16/765,495 2017-11-30 2018-11-30 Method for aggregating cell mass and device for aggregating cell mass Pending US20200318044A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017230609 2017-11-30
JP2017-230609 2017-11-30
PCT/JP2018/044196 WO2019107546A1 (ja) 2017-11-30 2018-11-30 細胞塊を集合させる方法及び細胞塊を集合させる装置

Publications (1)

Publication Number Publication Date
US20200318044A1 true US20200318044A1 (en) 2020-10-08

Family

ID=66663976

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/765,495 Pending US20200318044A1 (en) 2017-11-30 2018-11-30 Method for aggregating cell mass and device for aggregating cell mass

Country Status (3)

Country Link
US (1) US20200318044A1 (ja)
JP (1) JP6989828B2 (ja)
WO (1) WO2019107546A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113238316A (zh) * 2021-05-20 2021-08-10 北京京东方光电科技有限公司 导光板、背光模组及其制备方法、显示面板

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989913A (en) * 1998-07-02 1999-11-23 Charles Daniel Anderson Culture vessel for growing or culturing cells, cellular aggregates, tissues and organoids and methods for using the same
US20070131612A1 (en) * 2005-10-27 2007-06-14 Duffy Neil F Jr Cell separation method and apparatus
US20090258037A1 (en) * 2008-03-26 2009-10-15 The Government of the United States of America as represented by the Department of Veterans Affairs Vaccine development strategy using microgravity conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208483A (en) * 1978-09-21 1980-06-17 The University Of Toledo Tissue culture system
JP2002045173A (ja) * 2000-08-04 2002-02-12 Ii C T:Kk 細胞塊の培養方法およびバイオリアクター
JP2003070458A (ja) * 2001-09-04 2003-03-11 Mitsubishi Heavy Ind Ltd ３次元クリノスタット、細胞培養装置、生物育成装置、及び材料形成装置
JP2006304791A (ja) * 2005-03-31 2006-11-09 National Institute For Materials Science 三次元培養装置を用いた細胞集塊の大量形成法
JP5055479B2 (ja) * 2007-03-27 2012-10-24 株式会社ジェイテック 自動細胞培養装置
JP5103573B2 (ja) * 2007-09-07 2012-12-19 独立行政法人産業技術総合研究所 浮遊培養システム及び浮遊培養方法
WO2010143651A1 (ja) * 2009-06-09 2010-12-16 株式会社ジェイテック 回転培養ベッセル及びそれを用いた自動細胞培養装置
WO2013077423A1 (ja) * 2011-11-25 2013-05-30 国立大学法人京都大学 多能性幹細胞の培養方法
JP6341574B2 (ja) * 2013-03-21 2018-06-13 公立大学法人横浜市立大学 軟骨細胞の調製方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989913A (en) * 1998-07-02 1999-11-23 Charles Daniel Anderson Culture vessel for growing or culturing cells, cellular aggregates, tissues and organoids and methods for using the same
US20070131612A1 (en) * 2005-10-27 2007-06-14 Duffy Neil F Jr Cell separation method and apparatus
US20090258037A1 (en) * 2008-03-26 2009-10-15 The Government of the United States of America as represented by the Department of Veterans Affairs Vaccine development strategy using microgravity conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRIMM et al TISSUE ENGINEERING: Part B, Vol. 20, No. 6, 2014, pages 555-566 (Year: 2014) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113238316A (zh) * 2021-05-20 2021-08-10 北京京东方光电科技有限公司 导光板、背光模组及其制备方法、显示面板

Also Published As

Publication number Publication date
JPWO2019107546A1 (ja) 2020-11-19
WO2019107546A1 (ja) 2019-06-06
JP6989828B2 (ja) 2022-01-12

Similar Documents

Publication Publication Date Title
Liu et al. Stem cell engineering in bioreactors for large‐scale bioprocessing
Placzek et al. Stem cell bioprocessing: fundamentals and principles
AU2016256782B2 (en) Expansion of stem cells in hollow fiber bioreactors
JP7125717B2 (ja) 培養方法
US10100277B2 (en) Pluripotent stem cell expansion and passage using a stirred tank bioreactor
Bornes et al. Hypoxic culture of bone marrow-derived mesenchymal stromal stem cells differentially enhances in vitro chondrogenesis within cell-seeded collagen and hyaluronic acid porous scaffolds
Jossen et al. Mass production of mesenchymal stem cells—impact of bioreactor design and flow conditions on proliferation and differentiation
KR102353140B1 (ko) 배양용기
US10214715B2 (en) Bioreactor system for stem cell expansion
JP2019509047A (ja) 撹拌タンクバイオリアクタを用いた多能性幹細胞の増殖および継代
WO2018207907A1 (ja) 細胞培養容器
US20200318044A1 (en) Method for aggregating cell mass and device for aggregating cell mass
Tripura et al. Applications of human hematopoietic stem cells isolated and expanded from different tissues in regenerative medicine
JPWO2019049985A1 (ja) 細胞保存材料
JP2014060991A (ja) 多孔質中空糸の内腔を用いる幹細胞の培養方法
JP2017148001A (ja) 細胞スフェロイドの製造方法
Consolo et al. A computational model for the optimization of transport phenomena in a rotating hollow-fiber bioreactor for artificial liver
CN113846016A (zh) 一种高通量多孔阵列芯片、装置、制备方法及应用
Zhang et al. Application of bioreactor in stem cell culture
JP2010046053A (ja) シート状動物細胞塊培養組成物とその作成方法
Wakeman et al. Long‐term multilayer adherent network (MAN) expansion, maintenance, and characterization, chemical and genetic manipulation, and transplantation of human fetal forebrain neural stem cells
JP2016007207A (ja) ｉＰＳ細胞の大量培養方法
Xu et al. The opportunities and challenges regarding induced platelets from human pluripotent stem cells
Bosch-Fortea et al. Biomimetic Artificial Bone Marrow Niches for the Scale Up of Hematopoietic Stem Cells
Carreras et al. Long-Term Human Hematopoietic Stem Cell Culture in Microdroplets. Micromachines 2021, 12, 90

Legal Events

Date Code Title Description
AS Assignment

Owner name: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TANIGUCHI, HIDEKI;TADOKORO, TOMOMI;SAKASHITA, TETSUYA;AND OTHERS;SIGNING DATES FROM 20200302 TO 20200323;REEL/FRAME:052707/0783

Owner name: JAPAN AEROSPACE EXPLORATION AGENCY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TANIGUCHI, HIDEKI;TADOKORO, TOMOMI;SAKASHITA, TETSUYA;AND OTHERS;SIGNING DATES FROM 20200302 TO 20200323;REEL/FRAME:052707/0783

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER